Halper Sadeh LLC Encourages IMXI, CMA, HOLX Shareholders to Contact the Firm to Discuss Their Rights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Should l Buy HOLX?
Source: PRnewswire
Investigation Announcement: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales of International Money Express, Comerica Incorporated, and Hologic, Inc.
Shareholder Rights: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to learn about their rights and options regarding the proposed transactions.
Legal Representation: The firm offers to handle cases on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees.
Firm's Background: Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HOLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HOLX
Wall Street analysts forecast HOLX stock price to rise
12 Analyst Rating
0 Buy
12 Hold
0 Sell
Hold
Current: 75.590
Low
76.00
Averages
77.56
High
79.00
Current: 75.590
Low
76.00
Averages
77.56
High
79.00
About HOLX
Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Liquidia and Dianthus See Active Options Trading
- Liquidia Options Volume: Liquidia Corp (Ticker: LQDA) experienced an options trading volume of 9,692 contracts today, equating to approximately 969,200 shares, which represents about 48.1% of its average daily trading volume of 2 million shares over the past month, indicating heightened market interest in its future performance.
- High Call Option Activity: Among LQDA options, the $47.50 strike call option expiring on January 21, 2028, has seen particularly high activity with 3,100 contracts traded today, representing around 310,000 underlying shares, suggesting increased investor expectations for a price rise.
- Dianthus Options Trading: Dianthus Therapeutics Inc (Ticker: DNTH) recorded an options trading volume of 3,379 contracts today, equivalent to approximately 337,900 shares, which is about 48% of its average daily trading volume of 704,415 shares over the past month, reflecting market interest in its potential volatility.
- High Put Option Activity: The $50 strike put option for DNTH, expiring on March 20, 2026, has seen 1,659 contracts traded today, representing approximately 165,900 underlying shares, indicating investor concern regarding potential downside risks.
See More
RadNet Reports Record Q4 Revenue and Acquires Gleamer
- Performance Exceeds Expectations: RadNet's Q4 revenue rose 14.8% year-over-year to $547.7 million, surpassing the market expectation of $515.7 million, indicating strong imaging demand and efficiency improvements, which drove a 7.45% increase in share price.
- Adjusted EBITDA Growth: Adjusted EBITDA increased by 16.9% to $87.7 million, with EBITDA margin rising from 15.7% to 16.0%, reflecting the company's sustained growth in high-acuity imaging, enhancing confidence in future profitability.
- Strong Digital Health Segment: Digital Health revenue surged 48.2% to $27.9 million, with adjusted EBITDA also rising, indicating success in digital transformation and expected further business growth.
- Gleamer Acquisition Strengthens AI Strategy: RadNet announced an acquisition of Gleamer for up to €230 million, expected to enhance imaging efficiency through automation, addressing radiologist shortages, and significantly improving productivity and patient care quality by 2026.
See More
Hologic Receives FDA Approval for New HPV Testing
- FDA Approval: Hologic's Aptima® HPV Assay has received FDA approval, becoming the only mRNA-based HPV test, designed to enhance flexibility and choice in cervical cancer screening, which is expected to significantly improve screening efficiency for clinicians.
- Importance of Screening: It is estimated that by 2026, approximately 13,490 new cases of cervical cancer will be diagnosed in the U.S., with about 4,200 women dying from the disease; Hologic's testing can reduce these preventable deaths through early screening and timely follow-up.
- Clinical Research Support: The approval is based on one of the largest real-world HPV screening studies involving over 650,000 women, showing that the sensitivity of the Aptima HPV Assay is clinically comparable to that of an FDA-approved DNA-based HPV test, further enhancing its credibility in clinical applications.
- Diverse Screening Options: Hologic's portfolio now includes Pap + HPV co-testing, Pap testing, and HPV primary testing, providing multiple FDA-approved screening methods that help physicians select the most appropriate testing approach based on patient age and risk factors.
See More
Hologic Q4 Earnings Miss Expectations with Flat Revenue
- Earnings Miss: Hologic reported a Q4 non-GAAP EPS of $1.04, missing expectations by $0.06, indicating pressure on profitability that could undermine investor confidence.
- Flat Revenue: The company’s Q4 revenue stood at $1.05 billion, flat year-over-year but $20 million below market expectations, reflecting weak market demand that may impact future growth strategies.
- Challenging Outlook: Hologic indicated that the outlook for 2026 is more challenging due to halted product shipments, which could lead to a decline in market share, necessitating a reassessment of product lines and market strategies to address these challenges.
- Analyst Rating Watch: Following the earnings miss, analysts' quant ratings on Hologic may be affected, prompting investors to monitor subsequent rating changes to adjust their investment strategies.
See More
Hologic Scheduled to Announce Q4 Earnings on January 29th
- Earnings Announcement Date: Hologic (HOLX) is set to release its Q4 fiscal year 2023 earnings on January 29th after market close, with consensus EPS estimate at $1.10, reflecting a 2.7% year-over-year decline, and revenue estimate at $1.07 billion, indicating a 1.9% year-over-year increase.
- Historical Performance: Over the past two years, Hologic has consistently beaten EPS estimates 100% of the time and revenue estimates 75% of the time, demonstrating strong execution in financial forecasting.
- Estimate Revision Trends: In the last three months, EPS estimates have seen five upward revisions and no downward adjustments, while revenue estimates experienced four upward revisions and one downward, indicating growing market confidence in the company's future performance.
- Challenges and Opportunities: Despite facing challenges in product shipments for 2026, Hologic reported a non-GAAP EPS of $1.13, exceeding expectations by $0.03, and revenue of $1.05 billion, surpassing estimates by $20 million, showcasing the company's resilience in maintaining profitability amid adversity.
See More
Analysis and Outlook: The Fed Maintained Its Position, and Markets Followed Suit
- FOMC Meeting Insights: The first FOMC meeting of 2026 provided significant information for Federal Reserve observers.
- Market Reaction: Despite the insights from the meeting, there was little impact on stock market performance.
See More
Liquidia and Dianthus See Active Options Trading
- Liquidia Options Volume: Liquidia Corp (Ticker: LQDA) experienced an options trading volume of 9,692 contracts today, equating to approximately 969,200 shares, which represents about 48.1% of its average daily trading volume of 2 million shares over the past month, indicating heightened market interest in its future performance.
- High Call Option Activity: Among LQDA options, the $47.50 strike call option expiring on January 21, 2028, has seen particularly high activity with 3,100 contracts traded today, representing around 310,000 underlying shares, suggesting increased investor expectations for a price rise.
- Dianthus Options Trading: Dianthus Therapeutics Inc (Ticker: DNTH) recorded an options trading volume of 3,379 contracts today, equivalent to approximately 337,900 shares, which is about 48% of its average daily trading volume of 704,415 shares over the past month, reflecting market interest in its potential volatility.
- High Put Option Activity: The $50 strike put option for DNTH, expiring on March 20, 2026, has seen 1,659 contracts traded today, representing approximately 165,900 underlying shares, indicating investor concern regarding potential downside risks.
See More
RadNet Reports Record Q4 Revenue and Acquires Gleamer
- Performance Exceeds Expectations: RadNet's Q4 revenue rose 14.8% year-over-year to $547.7 million, surpassing the market expectation of $515.7 million, indicating strong imaging demand and efficiency improvements, which drove a 7.45% increase in share price.
- Adjusted EBITDA Growth: Adjusted EBITDA increased by 16.9% to $87.7 million, with EBITDA margin rising from 15.7% to 16.0%, reflecting the company's sustained growth in high-acuity imaging, enhancing confidence in future profitability.
- Strong Digital Health Segment: Digital Health revenue surged 48.2% to $27.9 million, with adjusted EBITDA also rising, indicating success in digital transformation and expected further business growth.
- Gleamer Acquisition Strengthens AI Strategy: RadNet announced an acquisition of Gleamer for up to €230 million, expected to enhance imaging efficiency through automation, addressing radiologist shortages, and significantly improving productivity and patient care quality by 2026.
See More
Hologic Receives FDA Approval for New HPV Testing
- FDA Approval: Hologic's Aptima® HPV Assay has received FDA approval, becoming the only mRNA-based HPV test, designed to enhance flexibility and choice in cervical cancer screening, which is expected to significantly improve screening efficiency for clinicians.
- Importance of Screening: It is estimated that by 2026, approximately 13,490 new cases of cervical cancer will be diagnosed in the U.S., with about 4,200 women dying from the disease; Hologic's testing can reduce these preventable deaths through early screening and timely follow-up.
- Clinical Research Support: The approval is based on one of the largest real-world HPV screening studies involving over 650,000 women, showing that the sensitivity of the Aptima HPV Assay is clinically comparable to that of an FDA-approved DNA-based HPV test, further enhancing its credibility in clinical applications.
- Diverse Screening Options: Hologic's portfolio now includes Pap + HPV co-testing, Pap testing, and HPV primary testing, providing multiple FDA-approved screening methods that help physicians select the most appropriate testing approach based on patient age and risk factors.
See More
Hologic Q4 Earnings Miss Expectations with Flat Revenue
- Earnings Miss: Hologic reported a Q4 non-GAAP EPS of $1.04, missing expectations by $0.06, indicating pressure on profitability that could undermine investor confidence.
- Flat Revenue: The company’s Q4 revenue stood at $1.05 billion, flat year-over-year but $20 million below market expectations, reflecting weak market demand that may impact future growth strategies.
- Challenging Outlook: Hologic indicated that the outlook for 2026 is more challenging due to halted product shipments, which could lead to a decline in market share, necessitating a reassessment of product lines and market strategies to address these challenges.
- Analyst Rating Watch: Following the earnings miss, analysts' quant ratings on Hologic may be affected, prompting investors to monitor subsequent rating changes to adjust their investment strategies.
See More
Hologic Scheduled to Announce Q4 Earnings on January 29th
- Earnings Announcement Date: Hologic (HOLX) is set to release its Q4 fiscal year 2023 earnings on January 29th after market close, with consensus EPS estimate at $1.10, reflecting a 2.7% year-over-year decline, and revenue estimate at $1.07 billion, indicating a 1.9% year-over-year increase.
- Historical Performance: Over the past two years, Hologic has consistently beaten EPS estimates 100% of the time and revenue estimates 75% of the time, demonstrating strong execution in financial forecasting.
- Estimate Revision Trends: In the last three months, EPS estimates have seen five upward revisions and no downward adjustments, while revenue estimates experienced four upward revisions and one downward, indicating growing market confidence in the company's future performance.
- Challenges and Opportunities: Despite facing challenges in product shipments for 2026, Hologic reported a non-GAAP EPS of $1.13, exceeding expectations by $0.03, and revenue of $1.05 billion, surpassing estimates by $20 million, showcasing the company's resilience in maintaining profitability amid adversity.
See More
Analysis and Outlook: The Fed Maintained Its Position, and Markets Followed Suit
- FOMC Meeting Insights: The first FOMC meeting of 2026 provided significant information for Federal Reserve observers.
- Market Reaction: Despite the insights from the meeting, there was little impact on stock market performance.
See More
